4. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Stock Price as of March 25: $634.14
52-week Low: $629.02
Number of Hedge Fund Holders: 68
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is engaged in discovering, inventing, developing, manufacturing, and commercializing medicines for treating various diseases. Dupixent® has been characterized as a critical growth driver for the company, with strong potential for further expansion. The drug’s efficacy throughout multiple inflammatory conditions as well as its favorable safety profile place it well for continued expansion into the new indications. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent® (dupilumab) in adults having moderate-to-severe bullous pemphigoid (BP). To provide a brief context, BP is a chronic, debilitating, and relapsing skin disease.
By targeting the underlying type 2 inflammation, which happens to be the critical driver for bullous pemphigoid, Dupixent has been categorized as the first investigational biologic to demonstrate sustained disease remission and reduce disease severity and itch as compared to the placebo in a clinical trial. In February, the US FDA accepted for Priority Review the supplemental Biologics License Application for Dupixent to treat BP. Notably, the FDA decision is expected by June 20, 2025. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s financial and commercial strength enables it to continue to invest in its industry-leading R&D pipeline.
Baron Funds, an investment management company, released its Q3 2024 investor letter. Here is what the fund said:
“We purchased Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), a biopharmaceutical company that was built on a foundation in basic scientific research and antibody development. The company has successfully developed several blockbuster medicines, including Eylea and Eylea HD for retinal diseases (such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy) and Dupixent for immunological and inflammatory diseases (such as atopic dermatitis, asthma, and COPD). While Eylea is nearing the end of its patent life and faces potential biosimilar competition, the company has been transitioning patients to Eylea HD, which is a higher dose, longer-acting formulation of Eylea, and Dupixent is growing rapidly through indication expansion. Beyond the current product portfolio, Regeneron has an exciting new product pipeline with over 35 candidates in various stages of development, including a novel treatment for treating severe food allergy, a combination checkpoint inhibitor therapy for melanoma, lung cancer and other solid tumors, biospecific antibodies for blood cancers, and Factor XI antibodies for blood clot prevention, among others. Based on Regeneron’s track record of success discovering and developing new drugs, we are optimistic the pipeline will deliver some successes, which we think will drive upside in the stock.”
